Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Repurposing Existing Medicines Is Key Part Of Pandemic Solution, Industry Insists
Executive Summary
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
You may also be interested in...
UK Weathers Challenges Of COVID-19 And Brexit
Departing BGMA leader Warwick Smith highlights successes in the UK off-patent industry’s response to the COVID-19 pandemic but offers unambiguous criticism of Brexit in the concluding part of an exclusive interview with Generics Bulletin.
Three Pillars Must Support Value Added Medicines In EU
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.
EMA Endorses Dexamethasone For COVID-19
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.